Zacks Investment Research lowered shares of Fresenius SE (NASDAQ:FSNUY) from a strong-buy rating to a hold rating in a research note issued to investors on Tuesday, October 3rd.

According to Zacks, “Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company’s business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany. “

Shares of Fresenius SE (NASDAQ FSNUY) traded down 0.53% on Tuesday, hitting $20.50. 17,201 shares of the stock were exchanged. The company’s 50 day moving average is $20.75 and its 200-day moving average is $20.98. The stock has a market cap of $45.45 billion and a PE ratio of 21.39. Fresenius SE has a 52-week low of $17.22 and a 52-week high of $22.30.

ILLEGAL ACTIVITY NOTICE: This report was posted by Marea Informative and is the sole property of of Marea Informative. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at

Fresenius SE Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Get a free copy of the Zacks research report on Fresenius SE (FSNUY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Stock Ratings for Fresenius SE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE and related stocks with our FREE daily email newsletter.